Navigation Links
Regeneron Reports First Quarter 2013 Financial and Operating Results
Date:5/3/2013

TARRYTOWN, N.Y., May 3, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial and operating results for the first quarter of 2013 and provided an update on development programs. 

The Company reported total revenues of $440 million in the first quarter of 2013, compared to $232 million in the first quarter of 2012.  Total revenues include EYLEA U.S. net product sales of $314 million in the first quarter of 2013, compared to $124 million in the first quarter of 2012.  The Company reported non-GAAP net income of $201 million, or $1.78 per diluted share, in the first quarter of 2013, compared to $40 million, or $0.37 per diluted share, in the first quarter of 2012.  Non-GAAP net income excludes non-cash share-based compensation expense, non-cash interest expense related to the Company's convertible senior notes, and non-cash income taxes.  The Company reported GAAP net income of $99 million, or $0.90 per diluted share, in the first quarter of 2013, compared to $12 million, or $0.11 per diluted share, in the first quarter of 2012. 

"The first quarter of 2013 was a productive quarter where we delivered sustained revenue and earnings growth," said Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron.  "EYLEA sales in the U.S. continue to enjoy strong growth and we are raising our estimate of full year U.S. EYLEA net sales to $1.25 to $1.325 billion in 2013.  The ex-U.S. launch of EYLEA by our partner, Bayer HealthCare, is also going very well and resulted in a positive contribution to our earnings this quarter.  Our broad, late-stage pipeline is making progress.  We expect our first data from the alirocumab Phase 3 program for reducing LDL cholesterol in the second half of 2013.  We reported positive data with our IL-4R inhibitor, dupilumab, in atopic dermatitis and additional data for dupilumab are expected in allergic ast
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
2. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Regeneron Announces March 2012 Investor Conference Presentations
5. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
7. Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
8. PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
9. Cytos Biotechnology Ltd Reports First Quarter 2013 Financial Results and Recent Development
10. InterMune Reports First Quarter 2013 Financial Results and Business Highlights
11. Cord Blood Banking Industry: 2013 Growth Opportunities Analysis in New Market Research Report at ReportsnReports.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... FT. LAUDERDALE, Fla. , Feb. 26, 2015 /PRNewswire/ ... discussed growth priorities driven by key research advancements ... Health segments at today,s Bank of America Merrill Lynch ... worldwide met the challenge of building grain supplies the ... expected to continue at the pace of the last ...
(Date:2/26/2015)... Feb. 26, 2015  NuGene International, Inc. ("NuGene") ... for skin and hair rejuvenation, has announced that ... of record for investor relations and strategic communications. ... distribution, sales and diversification strategies – and we ... prospective shareholders," stated Ali Kharazmi CEO of NuGene ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 The ... -12, at the Ernest N. Morial Convention Center ... (count as of February 19, 2015) displaying products ... industrial, academic, and government labs. The Exposition will ... but not limited to, analytical chemistry; drug discovery; ...
(Date:2/26/2015)... RURO, Inc., a leading LIMS, RFID ... – the latest update to the bestselling commercial-off-the-shelf sample ... a quick and easy method to gain better control ... RURO engineering has enhanced the system’s support for those ... of sample records. , "FreezerPro has become the ...
Breaking Biology Technology:DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3Pittcon 2015 Announces Exposition Highlights 2RURO Releases FreezerPro® version 6.2 2
... /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Alternext,US: SVA), a leading ... Bureau of Fengtai District in the City of Beijing suspended,the ... following a,report of the death of a minor in the ... of the vaccine two days prior. , ...
... "experimental luxuries" such as expensive spa and anti-aging treatments seek out ... else to pamper them, they pamper themselves by re-creating that same ... spa facial line, meets this growing demand for high quality treatments ... ...
... world, largely due to properties that render the materials ... of their most useful qualities, however - the ability ... - is also one of the most puzzling., This ... change shape to absorb energy rather than breaking apart, ...
Cached Biology Technology:Sinovac Releases Statement on Healive Vaccine Suspension 2ZhenSpa.com provides Spa Enthusiasts Affordable Alternatives for Expensive Spa Treatments 2ZhenSpa.com provides Spa Enthusiasts Affordable Alternatives for Expensive Spa Treatments 3ZhenSpa.com provides Spa Enthusiasts Affordable Alternatives for Expensive Spa Treatments 4Fast molecular rearrangements hold key to plastic's toughness 2Fast molecular rearrangements hold key to plastic's toughness 3
(Date:1/22/2015)... Washington , January 20, 2015 Investorideas.com, ... tech stocks, releases video from the CES 2015 (Consumer Electronics ... Apollo Robbins . Apollo shows how easily ... smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ... "Global Wearable Technologies Market and Applications, Opportunities, Industry ... Forecast 2014-2020" report to their offering. ... that can be worn on the user,s body ...
(Date:12/24/2014)... in December 2014, the 1U™ app has helped ... remember their usernames and passwords through replacing the antiquated system ... people who have struggled to remember usernames and passwords, ... on redefining identity, announced today that it is offering the ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
... Homo sapiens migrating out of Africa began ... humans hundreds of thousands of years before. Despite their ... over time, produced children with genes from both lineages. ... distinct populations remain alive in the genomes of humans ...
... Scientists have identified how a single gene in honey bees ... scientists from Michigan State University and Wayne State University unraveled ... current issue of Biology Letters . The gene, which ... role in the evolution of bees, ability to carry pollen. ...
... Elsevier, world-leading provider of scientific, technical and medical ... open access journal, Pathogenesis . ... The Royal College of Pathologists a professional membership ... and promoting excellence in the practice of Pathology. ...
Cached Biology News:When populations collide 2When populations collide 3When populations collide 4Single gene separates queen from workers 2Elsevier announces the launch of open access journal: Pathogenesis 2
Request Info...
Goat polyclonal to Factor VIII, prediluted ( Abpromise for all tested applications). Antigen: Full length native protein (purified) (Human): Factor VIII from blood. Entrez GeneID: 2157 Sw...
Anti-Bcl-G (CT) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
Affinity Purified Rabbit Anti-mouse sRANKL Biotinylated Polyclonal Antibody...
Biology Products: